Results 61 to 70 of about 16,194 (165)

Pangenotypic Direct Acting Antivirals Treatment for Chronic Hepatitis C Infection

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2020
Juferdy Kurniawan
doaj   +1 more source

Future destinations: how people cured of hepatitis C using direct acting antiviral drugs progress in a new HCV-free world. A thematic analysis

Harm Reduction Journal
Background The introduction of Direct-Acting Antivirals (DAAs) transformed Hepatitis C (HCV) treatment, despite this uptake of DAAs remains lower than required to meet the WHO Sustainable Development Goal (3.3). Treatment with interferon was suggested to
Sarah R. Donaldson, Andrew Radley, John F. Dillon   +2 more
doaj   +1 more source

Correction: The Impact of Organic Anion-Transporting Polypeptide (OATP) Variants on the Side Effects of Direct-Acting Antivirals in Hepatitis C Patients. [PDF]

Cureus
Altintas Z, Altintas E.
europepmc   +1 more source

Improving access to direct acting antivirals via a multimodal integrated care program in an addiction medicine clinic. [PDF]

Am J Addict
Zandvakili A, Rattenni J, Burton J, Guduguntla L, Osman M, Sabbagh S, Arndt S, Miskle B, Kaewpoowat Q, Ohl M, Weber A, Lynch A.   +11 more
europepmc   +1 more source

Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye. [PDF]

Turk J Gastroenterol
Gunduz A, Öztoprak NÇ, Sarı ND, Kurtaran B, Önlen Y, Senates E, Zerdali E, Karsen H, Batırel A, Ali RK, Güner R, Yamazhan T, Kose S, Erben N, Ince N, Köksal İ, Sarıgül Yıldırım F, Yoruk G, Komur S, Bal T, Kaya S, Esen Ş, Günal Ö, Yıldız IE, Inan D, Barut Ş, Namıduru M, Tosun S, Türker K, Sener A, Hızel K, Baykam N, Duygu F, Akıncı E, Can G, User U, Gül HC, Akbulut A, Çelebi G, Sünnetçioğlu M, Karabay O, Kumbasar Karaosmanoğlu H, Sırmatel F, Tabak F, Hep-C Turkey Study Group.   +44 more
europepmc   +1 more source

Treatment with Direct-Acting Antivirals in Patients with HCV Infection After Liver Transplantation. [PDF]

J Clin Med
Brzdęk M, Zarębska-Michaluk D, Tronina O, Laurans Ł, Janczewska E, Dybowska D, Parfieniuk-Kowerda A, Tudrujek-Zdunek M, Białkowska-Warzecha J, Janocha-Litwin J, Flisiak R.   +10 more
europepmc   +1 more source

Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV. [PDF]

AIDS
Chalouni M, Torgersen J, Rentsch CT, Van Santen DK, Jarrin I, Klein MB, Young J, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Nemeth J, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Miro JM, Berenguer J, Hernán MA, Lodi S.   +25 more
europepmc   +1 more source

Direct-Acting Antivirals Are a Milestone for Hepatitis C Virus Infection? Analysis of 15 Years of Patient and Diagnosis Data from a Region in Türkiye. [PDF]

J Clin Med
Yakupogullari Y, Tanrıverdi ES, Otlu B.
europepmc   +1 more source

Direct-acting antivirals and hepatocellular carcinoma recurrence

Journal of Public Health and Emergency, 2021
Nasser Mousa, Ahmed Abdel-Razik
openaire   +1 more source

Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies. [PDF]

Syst Rev
Kumburegama BWMB, Kristensen AT, Bjelakovic G, Nikolova D, Asante MA, Bjelakovic M, Koretz RL, Balakumar MM, Michelsen ME, Klingenberg SL, Gluud C.   +10 more
europepmc   +1 more source